Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

It has been about a month since the last earnings report for Ionis Pharmaceuticals (IONS). Shares have added about 0.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ionis Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, estimates revision flatlined during the past month.VGM ScoresCurrently, Ionis Pharmaceuticals has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookIonis Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerIonis Pharmaceuticals belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Zoetis (ZTS), has gained 3.7% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Zoetis reported revenues of $2.32 billion in the last reported quarter, representing a year-over-year change of +4.7%. EPS of $1.40 for the same period compares with $1.24 a year ago.For the current quarter, Zoetis is expected to post earnings of $1.41 per share, indicating a change of +2.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.4% over the last 30 days.Zoetis has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks